A carregar...
Romiplostim dose–response in patients with myelodysplastic syndromes
AIM: To characterize the romiplostim dose–response in subjects with low or intermediate-1 risk myelodysplastic syndromes (MDS) receiving subcutaneous romiplostim. METHODS: Data from 44 MDS subjects receiving subcutaneous romiplostim (dose range 300–1500 μg week(−1)) were used to develop a pharmacody...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Science Inc
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3690103/ https://ncbi.nlm.nih.gov/pubmed/23171070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12041 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|